AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Carbonic anhydrase 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P23280

UPID:

CAH6_HUMAN

Alternative names:

Carbonate dehydratase VI; Carbonic anhydrase VI; Salivary carbonic anhydrase; Secreted carbonic anhydrase

Alternative UPACC:

P23280; E7EMQ1; Q5FBW3; Q5FC00; Q96QX8; Q9UF03

Background:

Carbonic anhydrase 6, known by alternative names such as Carbonate dehydratase VI, Carbonic anhydrase VI, Salivary carbonic anhydrase, and Secreted carbonic anhydrase, plays a crucial role in the reversible hydration of carbon dioxide. Although its specific function in saliva remains to be fully elucidated, its enzymatic activity is vital for maintaining acid-base balance in various tissues.

Therapeutic significance:

Understanding the role of Carbonic anhydrase 6 could open doors to potential therapeutic strategies. Its unique presence in saliva and its enzymatic function suggest a specialized role that, once understood, could offer novel approaches to managing diseases related to acid-base imbalances.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.